Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10331461 | 1.00 | ECE1 (0.56) | ECE1KMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL29809632 | 0.90 | ECE1 (0.54) | ECE1KMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL29809741 | 0.88 | ECE1 (0.53) | ECE1KMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL29809818 | 0.87 | ECE1 (0.52) | ECE1KMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL2227252 | 0.85 | TAS1R3 (0.61) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL9838949 | 0.85 | ECE1 (0.64) | ECE1KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL9838941 | 0.85 | ECE1 (0.64) | ECE1KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL19588666 | 0.84 | MEN1 (0.52) | ECE1KMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL6860349 | 0.83 | ECE1 (0.62) | ECE1KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL22460628 | 0.83 | TAS1R3 (0.55) | KMT2AMEN1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409526-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | RETINA FOUND OF THE SOUTHWEST (US) | 2022-12-29 | — | — | US | claimed |
| EP-4054553-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | Retina Foundation of the Southwest (US) | 2022-09-14 | — | — | EP | claimed |
| US-20220409526-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | RETINA FOUND OF THE SOUTHWEST (US) | 2022-12-29 | — | — | US | disclosed |
| EP-4054553-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | Retina Foundation of the Southwest (US) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409526-A1 | COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS | PDE6C, STRA6, PDE6A | ECE1 1629/4885KMT2A 3986/4885MEN1 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.